1-3 of 3
Stephen S. Opat
Close
Sort by
Journal Articles

Molecular associations of response to the new-generation BTK inhibitor zanubrutinib in marginal zone lymphoma

Clinical Trials & Observations
Maciej Tatarczuch, Mark Waltham, Jake Shortt, Galina Polekhina, Eliza A. Hawkes, Shir-Jing Ho, Judith Trotman, Daniella Brasacchio, Melannie Co, Jessica Li, Vanitha Ramakrishnan, Karin Dunne, Stephen S. Opat, Gareth P. Gregory
Journal: Blood Advances
Blood Adv (2023) 7 (14): 3531–3539.
https://doi.org/10.1182/bloodadvances.2022009412
Published: 2023
Includes: Supplemental data
Journal Articles

Salvage radiotherapy is associated with durable response for a subset of patients with limited-stage refractory DLBCL

Clinical Trials & Observations
Jemima H. Miller, Michael Gilbertson, Michael P. MacManus, Andrew Wirth, Stephen S. Opat, Gareth P. Gregory
Journal: Blood Advances
Blood Adv (2021) 5 (23): 5112–5115.
https://doi.org/10.1182/bloodadvances.2021005061
Published: 2021
Includes: Supplemental data
Journal Articles

Bortezomib-based antibody depletion for refractory autoimmune hematological diseases

Clinical Trials & Observations
Sumita Ratnasingam, Patricia A. Walker, Huy Tran, Zane S. Kaplan, James D. McFadyen, Huyen Tran, Tse-Chieh Teh, Shaun Fleming, John V. Catalano, Sanjeev D. Chunilal, Anna Johnston, Stephen S. Opat, Jake Shortt
Journal: Blood Advances
Blood Adv (2016) 1 (1): 31–35.
https://doi.org/10.1182/bloodadvances.2016001412
Published: 2016